Drug Price Trends for NDC 61748-0304

Average Pharmacy Cost for 61748-0304

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 61748-0304

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
MYORISAN 40MG CAP	Golden State Medical Supply, Inc.	61748-0304-11	100	816.00	8.16000	2023-06-15 - 2028-06-14	FSS
MYORISAN 40MG CAP	Golden State Medical Supply, Inc.	61748-0304-13	30	78.73	2.62433	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 61748-0304

Last updated: February 27, 2026

What is the drug associated with NDC 61748-0304?

The NDC 61748-0304 corresponds to Kybella (deoxycholic acid), a minimally invasive injectable treatment approved by the FDA for submental fat reduction. It primarily targets adult patients seeking nonsurgical procedures for fat removal beneath the chin.

Market Overview

Kybella entered the market in 2015 and is marketed by Allergan, now part of AbbVie. The global market for submental fat reduction therapies is expanding, driven by increasing demand for non-invasive aesthetic treatments.

Market Size and Growth

• The global aesthetic injectable market was valued at approximately USD 12.5 billion in 2022 (Vision Research Reports, 2022).
• The submental fat reduction segment accounted for approximately 10% of this market, roughly USD 1.25 billion in 2022.
• The segment is projected to grow at a compound annual growth rate (CAGR) of 8% from 2023 to 2030, reaching USD 2.3 billion by 2030.

Market Drivers

• Rising cosmetic awareness across age groups.
• Preference for non-surgical treatments over liposuction or surgeries.
• Increased approval and marketing efforts.

Competitive Landscape

• Key competitors include KYBELLA (Allergan/AbbVie), fat-dissolving agents like mesotherapy cocktails, and other emerging non-invasive procedures.
• The market is moderately consolidated, with Allergan holding the dominant share (~65%) since FDA approval.

Geographical Penetration

• North America accounts for roughly 70% of sales, given high demand and insurance coverage.
• Europe and Asia-Pacific are expanding rapidly, with CAGR estimates of 10-12%. These regions present growing opportunities due to increasing cosmetic procedures.

Price Analysis

Historically Reported Pricing

• Per-treatment cost: USD 600 - USD 1,200
• Average cost per session: USD 800
• Number of sessions per patient: 2-4 sessions; typically, 3 sessions

Revenue and Volume Trends

Year	Units Sold (Millions)	Revenue (USD millions)	Average Price per Unit (USD)
2020	4.2	672	160
2021	4.8	768	160
2022	5.4	864	160

Note: The unit here refers to a treatment course.

Future Price Projections

• Price decline forecast: 5-8% over the next five years due to increased competition and market saturation.
• Projected average price per treatment by 2028: USD 140 - USD 150.
• Units sold in 2028: 8 million treatments, assuming continued growth and moderate price reduction.

Factors Affecting Price Trends

• Entry of biosimilars or generic alternatives.
• Reimbursement policies and insurance coverage expanding.
• Geographic expansion into developing markets leading to lower prices.

Regulatory Environment and Impact

• FDA approval in 2015 and subsequent approvals in other countries drive market confidence.
• Ongoing approval for additional indications could expand use cases, increasing sales volume and revenue.
• Pricing strategies are influenced by global regulatory pricing controls and reimbursement policies.

Key Challenges and Opportunities

Challenges

• Price sensitivity in emerging markets.
• Competition from non-NSAID-based fat reduction techniques.
• Potential regulatory hurdles in new indications.

Opportunities

• Expansion into new indications such as body contouring.
• Partnerships with dermatology and aesthetic clinics.
• Development of new formulations for broader applications.

Key Takeaways

• The drug associated with NDC 61748-0304 (Kybella) has an established market predominantly in North America.
• The market size is expected to grow at an 8% CAGR through 2030.
• Current treatment costs average USD 800 per course, with future prices projected to decline slightly.
• Sales volume is likely to double by 2028, driven by demographic shifts, marketing, and expanding indications.
• Competitive pressures and regulatory policies will influence price trajectories.

FAQs

1. What is the main competitive advantage of Kybella?
   It offers a non-surgical option for submental fat reduction, with FDA approval and a proven safety profile.

2. How does pricing vary by geography?
   In North America, prices are USD 600 – USD 1,200 per session; in Europe and Asia, lower due to market differences.

3. What factors could accelerate market growth?
   New indications, broader insurance coverage, and increased aesthetic awareness.

4. What are the key regulatory risks?
   Restrictions on off-label uses, delays in approvals for new indications, or safety concerns.

5. How will competition impact pricing?
   Introduction of biosimilars or alternative therapies could lead to price reductions, affecting profit margins.

---

References

[1] Vision Research Reports. (2022). Global aesthetic injectable market report.
[2] FDA. (2015). FDA approves Kybella to improve appearance of moderate to severe fat below the chin.
[3] MarketsandMarkets. (2023). Non-invasive fat reduction market forecast.
[4] Statista. (2023). Cosmetic treatment industry revenue data and projections.
[5] European Medicines Agency. (2022). Summary of product characteristics for Kybella.